Daptomycin Drug Asset Due Diligence Report 2026

This Daptomycin Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

105

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Daptomycin can convert its Polypeptide antibiotic, Cyclic Peptide profile and Not disclosed biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Daptomycin (query alias: daptomycin)
Modality / target	Polypeptide antibiotic, Cyclic Peptide; Not disclosed; Not disclosed
Highest global status	Approved
Originator	Not disclosed
Active developers	Not disclosed

The MCP disease footprint includes no disclosed indication. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT06637332	Phase 4	Recruiting	300	Desirability of Outcome Ranking (DOOR)
EUCTR2021-004108-16-AT	Phase 4	Not Recruiting	64	PRIMARY ENDPOINTS Correlating of the plasma to tissue penetration ratio (determined as AUCSC tissue/AUCplasma-unbound for microdialysis over the investigated dosing interval and as CELF/Cplasma-unbound for ELF at the time of the BAL procedure) with the investigated selected biomarkers described below. Measurements for the primary endpoints: PK endpoints For plasma, BAL and subcutaneous tissue: - Determination of the PK of the included antibiotics in lung, subcutaneous tissue and plasma in critically ill patients o Area under the time-concentration curve of the unbound drug concentrations from time point zero to last observed concentration (AUC0-n) (only for plasma and subcutis) o Maximum post-dose drug concentration in the respective investigated compartment (Cmax) o Mean (or average) concentration that a drug achieves in the respective investigated compartment (Caverage) o Time to reach maximum drug concentration in the respective investigated compartment (Tmax) o Half-life (T1/2) o Subcutaneous tissue to plasma ratios (AUCSC/AUCplasma, Cmax SC/Cmax plasma) o ELF to plasma ratios (CBAL/C plasma) Only for plasma: - Volume of distribution (Vd) - Clearance (Cl) - Protein binding (PB)
NCT05156437	Phase 4	Terminated	5	All-cause Mortality at Six (6) Months Post-surgery.

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL)

Phase 4; n=5; evaluation: not stated. Reported fields: Other (Not Including Serious) Adverse Events = 0 Participants ; -; -

Pharmacokinetics and safety of daptomycin administered subcutaneously in healthy volunteers: a single-blinded randomized crossover trial

Phase 1; n=12; evaluation: Positive. Reported fields: AUC0-24 = 937.3 μg·h/mL ( 102.5); AUC0-24 = 1056.3 μg·h/mL ( 123.5)

Dalbavancin as an Option for Treatment of S. Aureus Bacteremia (DOTS): A Phase 2b, Multicenter, Randomized, Open-Label, Assessor-Blinded Superiority Study to Compare the Efficacy and Safety of Dalbavancin to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated S. Aureus Bacteremia

Phase 2; n=200; evaluation: not stated. Reported fields: Desirability of Outcome Ranking (DOOR): Pr(Better DOOR in dalbavancin arm) = 47.70(95% CI, 39.84 - 55.68); Desirability of Outcome Ranking (DOOR): Pr(Better DOOR in dalbavancin arm) = 47.70(95% CI, 39.84 - 55.68); Desirability of Outcome Ranking (DOOR): Pr(Better DOOR in dalbavancin arm) = 47.70(95% CI, 39.84 - 55.68)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Daptomycin addresses its disclosed development indications. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Polypeptide antibiotic, Cyclic Peptide—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2001-01-07	Cubist Pharmaceuticals and Gilead Sciences Announce European Commercialization Agreement for Investigational Antibacterial Agent Cidecin™	Phase 3	US$13.0M upfront; US$31.0M milestones
1997-11-01	Cubist to Purchase 2 Percent Reduction in Cubicin Royalty Rate From Lilly	Not disclosed	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO